Component

Circulating apolipoprotein B concentration

Circulating apolipoprotein B concentration. Experimental scope belongs to the associated record.

3 recorded relationships. Experimental role, claim status and evidence remain attached to each record.

Read recorded mechanisms Open recursive mind map

How nutrients influence it

Every nutrient with a recorded effect on this component, credited to the nutrient that acted rather than the chapter that recorded it. Open a nutrient to see the findings and the conditions they were measured under.

How nutrients reach it in more than one step

Chains of two or more recorded steps that end here, grouped by the nutrient they start from. Each step is a separate finding, so a chain is a route a mechanism could take, not proof that it does.

Tracing routes…

What it does

Every recorded relationship this component is part of, grouped by its role. Plain wording comes first; the technical statement follows.

Recorded relationships

What acts on it

  1. A median dose of 3.5 grams per day of oat beta-glucan significantly lowered LDL-cholesterol by -0.19 with 95% CI -0.23 to -0.14 mmol/l, non-HDL-cholesterol by -0.20 with 95% CI -0.26 to -0.15 mmol/l and apoB by -0.03 with 95% CI -0.05 to -0.02 g/l compared with control interventions, and there was evidence for considerable unexplained heterogeneity in the analysis of LDL-cholesterol with I-squared of 79% and non-HDL-cholesterol with I-squared of 99%.

    Oat mixed-linkage beta-(1->3)/(1->4)-glucan → Circulating apolipoprotein B concentration source_derived_draftungraded
    Experimental context and source evidence
    evidence_span
    {"source_cache": "artifacts/glucan-research/27724985.abstract.txt", "locator": "Indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "a764416442dac76f7e70e8b6a509b5913693d6a8f7b95cd03beb4567f5b5c9f3", "start_char": 0, "end_char": 1647, "text_sha256": "a764416442dac76f7e70e8b6a509b5913693d6a8f7b95cd03beb4567f5b5c9f3"}
    experimental_model
    Systematic review and random-effects meta-analysis of 58 randomised controlled trials in 3974 participants
    exposure
    Diets enriched with oat beta-glucan at a median 3.5 grams per day for at least three weeks
    limitations
    Considerable unexplained heterogeneity, with I-squared of 79 percent for LDL and 99 percent for non-HDL cholesterol. These are pooled estimates, not the expected effect of any particular product.
    nutrient_topic
    Beta-glucan research collection; topical membership is not evidence of a direct clinical effect, and each preparation is recorded as its own entity with no family link joining any pair. · Beta-glucan
    organism
    Human
    plain_language
    The particle count falls too, not just the cholesterol carried in it.
    primary_references
    [bg-p27724985] The effect of oat β-glucan on LDL-cholesterol, non-HDL-cholesterol and apoB for CVD risk reduction: a systematic review and meta-analysis of randomised-controlled trials. (2016). https://pubmed.ncbi.nlm.nih.gov/27724985/ DOI: 10.1017/s000711451600341x
    tissue_or_cell_type
    Serum lipoproteins

    Beta-glucan: a structural family rather than an agent, what decides whether a bound glucan actually signals, the complement route that a cereal and a yeast preparation share, and the unequal human evidence behind each (2026-09-22) · lines 502–513

    AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · Systematic review and random-effects meta-analysis of 58 randomised controlled trials in 3974 participants · source_derived_draft · unverified_draft

    ### bg-apob-and-non-hdl-move-too A median dose of 3.5 grams per day of oat beta-glucan significantly lowered LDL-cholesterol by -0.19 with 95% CI -0.23 to -0.14 mmol/l, non-HDL-cholesterol by -0.20 with 95% CI -0.26 to -0.15 mmol/l and apoB by -0.03 with 95% CI -0.05 to -0.02 g/l compared with control interventions, and there was evidence for considerable unexplained heterogeneity in the analysis of LDL-cholesterol with I-squared of 79% and non-HDL-cholesterol with I-squared of 99%. Condition category: normal nutrient_topic: Beta-glucan research collection; topical membership is not evidence of a direct clinical effect, and each preparation is recorded as its own entity with no family link joining any pair. plain_language: The particle count falls too, not just the cholesterol carried in it. organism: Human tissue_or_cell_type: Serum lipoproteins experimental_model: Systematic review and random-effects meta-analysis of 58 randomised controlled trials in 3974 participants limitations: Considerable unexplained heterogeneity, with I-squared of 79 percent for LDL and 99 percent for non-HDL cholesterol. These are pooled estimates, not the expected effect of any particular product. exposure: Diets enriched with oat beta-glucan at a median 3.5 grams per day for at least three weeks evidence_span: {"source_cache": "artifacts/glucan-research/27724985.abstract.txt", "locator": "Indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "a764416442dac76f7e70e8b6a509b5913693d6a8f7b95cd03beb4567f5b5c9f3", "start_char": 0, "end_char": 1647, "text_sha256": "a764416442dac76f7e70e8b6a509b5913693d6a8f7b95cd03beb4567f5b5c9f3"} [bg-p27724985] The effect of oat β-glucan on LDL-cholesterol, non-HDL-cholesterol and apoB for CVD risk reduction: a systematic review and meta-analysis of randomised-controlled trials. (2016). https://pubmed.ncbi.nlm.nih.gov/27724985/ DOI: 10.1017/s000711451600341x
    Complete structured claim and evidence

  2. Apolipoprotein B fell by an additional 3.42 mg/dL with berberine versus placebo, a secondary endpoint.

    Berberine → Circulating apolipoprotein B concentration source_derived_draftungraded
    Experimental context and source evidence
    evidence_span
    {"source_cache": "artifacts/berberine-research/41543854.abstract.txt", "locator": "Primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "1093df47a715746d0334d7d7f3c9c0c71e502b43b47b383b21900b982d6ad021", "start_char": 0, "end_char": 2354, "text_sha256": "1093df47a715746d0334d7d7f3c9c0c71e502b43b47b383b21900b982d6ad021"}
    experimental_model
    Multicenter double-blind randomized placebo-controlled trial
    exposure
    Berberine 1 g/day for six months
    limitations
    No significant primary fat-reduction effect. Lipid endpoints were secondary; this population differs from diabetes trials and does not resolve every liver-disease subgroup.
    nutrient_topic
    Berberine research collection; topical membership is not evidence of a direct dietary effect. · Berberine
    organism
    337 diabetes-free adults with obesity and MASLD in China
    plain_language
    A separate lipoprotein marker changed; cardiovascular events were not the outcome.
    primary_references
    [berberine-p41543854] Berberine and Adiposity in Diabetes-Free Individuals With Obesity and MASLD: A Randomized Clinical Trial. (2026). https://pubmed.ncbi.nlm.nih.gov/41543854/ DOI: 10.1001/jamanetworkopen.2025.54152
    tissue_or_cell_type
    CT visceral adipose area and liver fat; lipid endpoints

    Berberine: metabolism, nutrient connections and drug interactions (2026-09-17) · lines 1286–1297

    AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · Multicenter double-blind randomized placebo-controlled trial · source_derived_draft · unverified_draft

    ### berberine-masld-apob Apolipoprotein B fell by an additional 3.42 mg/dL with berberine versus placebo, a secondary endpoint. Condition category: normal nutrient_topic: Berberine research collection; topical membership is not evidence of a direct dietary effect. plain_language: A separate lipoprotein marker changed; cardiovascular events were not the outcome. organism: 337 diabetes-free adults with obesity and MASLD in China tissue_or_cell_type: CT visceral adipose area and liver fat; lipid endpoints experimental_model: Multicenter double-blind randomized placebo-controlled trial limitations: No significant primary fat-reduction effect. Lipid endpoints were secondary; this population differs from diabetes trials and does not resolve every liver-disease subgroup. exposure: Berberine 1 g/day for six months evidence_span: {"source_cache": "artifacts/berberine-research/41543854.abstract.txt", "locator": "Primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "1093df47a715746d0334d7d7f3c9c0c71e502b43b47b383b21900b982d6ad021", "start_char": 0, "end_char": 2354, "text_sha256": "1093df47a715746d0334d7d7f3c9c0c71e502b43b47b383b21900b982d6ad021"} [berberine-p41543854] Berberine and Adiposity in Diabetes-Free Individuals With Obesity and MASLD: A Randomized Clinical Trial. (2026). https://pubmed.ncbi.nlm.nih.gov/41543854/ DOI: 10.1001/jamanetworkopen.2025.54152
    Complete structured claim and evidence

  3. The same trial reported a 4 mg/dL (5%) apolipoprotein B reduction from baseline at week 16 and a significant comparison with placebo.

    Pantethine → Circulating apolipoprotein B concentration source_derived_draftungraded
    Experimental context and source evidence
    cross_nutrient
    false
    evidence_location
    Primary indexed abstract.
    experimental_model
    Randomized triple-blind placebo-controlled 16-week trial in 120 adults at low-to-moderate cardiovascular risk
    exposure
    TLC diet begun four weeks before randomization and continued; 60 per group; pantethine 600 mg/day for weeks 1–8 and 900 mg/day for weeks 9–16.
    limitations
    Lipid markers rather than cardiovascular events; pantethine is a derivative, not dietary B5 repletion. Absolute changes were small. Industry-associated authors; full methods were not retrieved.
    nutrient_topic
    Pantothenic acid (vitamin B5) research collection; topical membership is not evidence of a direct dietary effect. · Pantothenate (vitamin B5)
    organism
    Homo sapiens
    plain_language
    A related lipoprotein marker also decreased modestly.
    primary_references
    [b5-clin-rumberger2011] Pantethine, a derivative of vitamin B(5) used as a nutritional supplement, favorably alters low-density lipoprotein cholesterol metabolism in low- to moderate-cardiovascular risk North American subjects: a triple-blinded placebo and diet-controlled investigation. (2011). https://pubmed.ncbi.nlm.nih.gov/21925346/ DOI: 10.1016/j.nutres.2011.08.001
    tissue_or_cell_type
    Circulating lipids and lipoproteins

    Pantothenic acid (vitamin B5): coenzyme A, deficiency and nutrient interactions (2026-09-17) · lines 1397–1409

    AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · Randomized triple-blind placebo-controlled 16-week trial in 120 adults at low-to-moderate cardiovascular risk · source_derived_draft · unverified_draft

    ### b5-clin-pantethine-apob-2011 The same trial reported a 4 mg/dL (5%) apolipoprotein B reduction from baseline at week 16 and a significant comparison with placebo. Condition category: normal nutrient_topic: Pantothenic acid (vitamin B5) research collection; topical membership is not evidence of a direct dietary effect. plain_language: A related lipoprotein marker also decreased modestly. organism: Homo sapiens tissue_or_cell_type: Circulating lipids and lipoproteins experimental_model: Randomized triple-blind placebo-controlled 16-week trial in 120 adults at low-to-moderate cardiovascular risk limitations: Lipid markers rather than cardiovascular events; pantethine is a derivative, not dietary B5 repletion. Absolute changes were small. Industry-associated authors; full methods were not retrieved. exposure: TLC diet begun four weeks before randomization and continued; 60 per group; pantethine 600 mg/day for weeks 1–8 and 900 mg/day for weeks 9–16. cross_nutrient: false evidence_location: Primary indexed abstract. [b5-clin-rumberger2011] Pantethine, a derivative of vitamin B(5) used as a nutritional supplement, favorably alters low-density lipoprotein cholesterol metabolism in low- to moderate-cardiovascular risk North American subjects: a triple-blinded placebo and diet-controlled investigation. (2011). https://pubmed.ncbi.nlm.nih.gov/21925346/ DOI: 10.1016/j.nutres.2011.08.001
    Complete structured claim and evidence

In the sources

Preserved passages that mention this component, quoted exactly. Open one to read it in context.

    This is a research prototype built from draft material. It is not medical advice, and its statements still await verification against the original studies.

    Evidence, AI assistance and curation standards